Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer

Prostate Cancer Clinical Trial

Official title: Real-time Image-guided Ultra-hypofractionated Focal Boost to Intraprostatic Lesion(s) With Lymph Node Irradiation for a Very High High-risk Localized Prostate Cancer (the HYPO-RT-PC Boost Trial)

Status Recruiting

Clinical Trial Summary

HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with node-negative high risk localized prostate cancer.

Clinical Trial Description

HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with node-negative high risk localized prostate cancer. 76 participants will be enrolled in the study. Specific aims of the study are: - To study the feasibility of ultra-hypofractionation target lesion boost for node-negative very high-risk prostate cancer together with lymph node irradiation (primary outcome). - To study the effectiveness of ultra-hypofractionated target lesion boost for high-risk prostate cancer. - To study the feasibility of defining focal boost during concomitant androgen deprivation therapy with advanced functional imaging methods. ;

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT06220435
• Study type: Interventional
• Source: Region Skane
• Contact: Adalsteinn Gunnlaugsson, MD, PhD
• Phone: +46 4617 6268
• Email: Adalsteinn.Gunnlaugsson@skane.se
• Status: Recruiting
• Phase: N/A
• Start date: September 25, 2023
• Completion date: September 1, 2031